

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

CellMinerCDB

RRID:SCR_025649

Type: Tool

Proper Citation

CellMinerCDB (RRID:SCR_025649)

Resource Information

URL: <https://discover.nci.nih.gov/rsconnect/cellminerfdb/>

Proper Citation: CellMinerCDB (RRID:SCR_025649)

Description: Web application integrating cancer cell line pharmacogenomics. Enables exploration and analysis of cancer cell line pharmacogenomic data across different sources. Focuses on cancer patient-derived human cell line molecular and pharmacological data. CellMinerCDB (v1.2) includes several improvements.

Synonyms: , Cell Miner CDB, CellMiner Cross-Database, CellMinerCDB 1.2

Resource Type: software resource, web application

Defining Citation: [PMID:30553813](#), [PMID:30553813](#)

Keywords: integrating cancer cell line pharmacogenomics, exploration and analysis of cancer cell line pharmacogenomic data, exploration and analysis, cancer cell line, pharmacogenomic data

Funding: NCI ;
NIGMS P41 GM103504

Availability: Free, Freely available,

Resource Name: CellMinerCDB

Resource ID: SCR_025649

Record Creation Time: 20240824T053240+0000

Record Last Update: 20260905T133503+0000

Ratings and Alerts

No rating or validation information has been found for CellMinerCDB.

No alerts have been found for CellMinerCDB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yoo J, et al. (2026) Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer. *Signal transduction and targeted therapy*, 11(1).

Zeng PYF, et al. (2026) Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer. *Cell reports. Medicine*, 7(6), 102820.

Xu C, et al. (2025) Single-cell and spatial transcriptomics reveal a potential role of ATF3 in brain metastasis of lung adenocarcinoma. *Translational lung cancer research*, 14(1), 209.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. *Cancer research communications*, 5(2), 375.

Li C, et al. (2025) Anticancer drug synergy prediction based on CatBoost. *PeerJ. Computer science*, 11, e2829.

Tabata S, et al. (2025) Context-Specific Metabolic Alterations in HPRT1 Knockout Cells Within a 3D Culture System. *Cancer medicine*, 14(23), e71452.

Masood MBE, et al. (2025) Integrated pan-cancer analysis revealed therapeutic targets in the ABC transporter protein family. *PloS one*, 20(5), e0308585.

Smith NJ, et al. (2025) Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma. *The EMBO journal*, 44(1), 1.

Gu Y, et al. (2025) HIG-Syn: a hypergraph and interaction-aware multigranularity network for predicting synergistic drug combinations. *Bioinformatics (Oxford, England)*, 41(Supplement_1), i86.

Li J, et al. (2025) Protocol for tumor prognostic prediction, molecular stratification, and target discovery using a machine learning-driven approach. *STAR protocols*, 6(4), 104130.

Mizunuma M, et al. (2024) Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. *Cancer research communications*, 4(8), 2101.

Onji H, et al. (2024) Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. *Oncogene*, 43(32), 2475.

Nakasuka F, et al. (2024) The role of cytidine 5'-triphosphate synthetase 1 in metabolic rewiring during epithelial-to-mesenchymal transition in non-small-cell lung cancer. *FEBS open bio*, 14(9), 1570.

Small SH, et al. (2024) Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML. *Blood neoplasia*, 1(4), 100037.

Baldasici O, et al. (2022) Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients. *International journal of molecular sciences*, 23(20).

Jo U, et al. (2021) Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. *Molecular cancer therapeutics*, 20(8), 1431.

Chen P, et al. (2021) Aberrant methylation modifications reflect specific drug responses in small cell lung cancer. *Genomics*, 113(3), 1114.

Yao X, et al. (2020) A membrane transporter determines the spectrum of activity of a potent platinum-acridine hybrid anticancer agent. *Scientific reports*, 10(1), 15201.